Showing 8 of 8 recruiting trials for “Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion”
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Real-World Treatment Study of Koselugo (Selumetinib)
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
👨⚕️ Carlos Romo, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins📍 1 site📅 Started Feb 2024View details ↗
A Study of Avutometinib for People With Solid Tumor Cancers
👨⚕️ Sameer Farouk Sait, MD, Memorial Sloan Kettering Cancer Center📍 2 sites📅 Started Oct 2023View details ↗
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
RecruitingNCT04395495 ↗
RASopathy Biorepository
👨⚕️ Kathryn N Weaver, MD, Children's Hospital Medical Center, Cincinnati📍 1 site📅 Started Jun 2017View details ↗
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →